Newsroom
Newsroom
Blog Posts
Earlier this month, my cofounder Kristy Hawkins and I presented at SynBioBeta 2020, the flagship conference for the synthetic biology community. This year’s virtual event...
Blog Posts
As a part of our new “Meet the Team” series, we hear from Ken Takeoka, Antheia’s very first employee and a Scientist III. Read on...
Blog Posts
It’s a momentous day for my research team at Stanford University. Today, we’ve announced a new paper published in Nature that describes the first successful...
Blog Posts
Over the last 150 years, the pharmaceutical industry has focused on decoupling the production of medicinal compounds from their sources in the natural world, which...
Blog Posts
We started Antheia four years ago with a steadfast commitment to help build a more robust drug supply chain – one that delivers the right...
Blog Posts
mericans spend over $300 billion on pharmaceutical drugs every year. In normal times, the supply chain behind these drugs is designed to go unnoticed......
Industry News
Antheia and Olon have announced a continuation of partnership, leveraging Olon’s fermentation infrastructure for the manufacture of Antheia’s early products...
Press Releases
Antheia and Olon established this partnership in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since played a pivotal role as a CDMO...
Press Releases
Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMS and APIs...
Industry News
With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell therapy,...
Industry News
Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology......
Industry News
Antheia, a Menlo Park CA-based synthetic biology company, raised $73M in Series B funding. The round was led by Viking Global Investors with participation from...
Industry News
Antheia, a synthetic biology company working to develop plant-inspired medicine, has officially secured a fresh $73 million in Series B funding......
Industry News
Antheia, a synthetic biology company cofounded and led by Stanford University bioengineer Christina Smolke, has raised $73 million in series B financing......
Industry News
Antheia Inc., Menlo Park, $73 million: Viking Global Investors led the Series B funding of this company that's making plant-based medicines using synthetic biology. Sherpalo...
Blog Posts
Earlier this month, my cofounder Kristy Hawkins and I presented at SynBioBeta 2020, the flagship conference for the synthetic biology community. This year’s virtual event...
Blog Posts
As a part of our new “Meet the Team” series, we hear from Ken Takeoka, Antheia’s very first employee and a Scientist III. Read on...
Blog Posts
It’s a momentous day for my research team at Stanford University. Today, we’ve announced a new paper published in Nature that describes the first successful...
Blog Posts
Over the last 150 years, the pharmaceutical industry has focused on decoupling the production of medicinal compounds from their sources in the natural world, which...
Blog Posts
We started Antheia four years ago with a steadfast commitment to help build a more robust drug supply chain – one that delivers the right...
Blog Posts
mericans spend over $300 billion on pharmaceutical drugs every year. In normal times, the supply chain behind these drugs is designed to go unnoticed......